Condition category
Mental and Behavioural Disorders
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
Rhodiola rosea is a traditional herbal medicine. The aim of this study is to look at the possible influence of Rhodiola rosea Extract WS® 1375 on visual attention and mental resource allocation in healthy volunteers at risk of stress.

Who can participate?
Healthy volunteers aged 30 to 50 who work on a computer for at least 15 hours per week

What does the study involve?
All participants take Rhodiola rosea Extract WS 1375 orally for 12 weeks and its effects on attention and dual task performance are assessed.

What are the possible benefits and risks of participating?
Rhodiola rosea extract may relieve symptoms associated with stress such as fatigue and exhaustion, and improve physical and mental work capacities under stressful conditions. There are no reported side effects related to Rhodiola rosea extract.

Where is the study run from?
Universitätsklinikum Schleswig-Holstein (Germany)

When is the study starting and how long is it expected to run for?
March 2012 to July 2013

Who is funding the study?
Dr Willmar Schwabe GmbH & Co. KG (Germany)

Who is the main contact?
Prof. Thomas Münte

Trial website

Contact information



Primary contact

Prof Thomas Münte


Contact details

Universitätsklinikum Schleswig-Holstein
Campus Lübeck
Klinik für Neurologie
Ratzeburger Allee 160

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Single center, open-label clinical trial to study the effects of Rhodiola rosea extract WS 1375 on neuropsychological and neurophysiological measures of attention and mental resource allocation in healthy volunteers


Study hypothesis

To gain initial insight in the possible influence of Rhodiola rosea extract WS 1375 on visual attention and mental resource allocation in healthy subjects at risk for stress symptomatology.

Ethics approval

Medical Association of Schleswig-Holstein [Ethik Kommission des Universitätsklinikums Schleswig-Holstein], 14/02/2012, ref: 11-244

Study design

Single-center open-label exploratory trial

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Neuropsychological and neurophysiological measures


One treatment arm only - Rhodiola rosea Extract WS 1375 (2 x 200mg) administered orally for 12 weeks.

Intervention type



Not Applicable

Drug names

Primary outcome measure

1. Attention Network Task
2. Go/NoGo Test
3. Divided Attention Test
4. Number Connection Test
5. Beck Depression Inventory II
6. Recent Perceived Stress Questionnaire
7. Event-related potentials

Secondary outcome measures

No secondary outcome measures

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Healthy male or female volunteers aged 30 to 50 years (both inclusive)
2. Signed Informed consent in accordance with the legal requirements
3. Sufficient language skills, readiness, and ability on the part of the subject to comply with the physicians instructions, respond to all interview questions, and to fill in the self-assessment scales without evident difficulties and without the assistance of an interpreter
4. Participants are required to work with a computer at least 15 hrs per week
5. Self-report of occasional visual and mental fatigue during computer work (scores 5 on at least 3 questions of the Ermdung und Computerarbeit questionnaire)

Participant type

Healthy volunteer

Age group




Target number of participants

50 subjects eligible for treatment

Participant exclusion criteria

1. Participation in another experimental drug trial at the same time or within the past 12 weeks before enrollment
2. Current hospitalization of the subject
3. Any clinically significant disease
4. Risk of suicide
5. History or evidence of alcohol and/or substance abuse or dependence, particularly of sedatives, hypnotics and anxiolytics within the last 5 years
6. History of Axis I disorders according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) at least one year before enrollment
7. History of head trauma that might be causally related to cognitive impairment
8. Non-medical psychiatric treatment (e.g., specific standardized psychotherapy) at least 4 weeks before the study
9. Unacceptability to discontinue or likelihood to need medication during the study that is prohibited as concomitant treatment
10. Any clinically relevant hepatic, renal (serum creatinine or serum ASAT, ALAT or Gamma GT above 3 times the upper limit of the reference range), cardiovascular, respiratory, cerebrovascular, metabolic disorder or progressive diseases as cancer (exception: prostate cancer T1N0M0 which does not require treatment within the next 7 months except hormone therapy), haematologic diseases or thyroid insufficiency, epilepsy or a history of seizure disorder or treatment with anticonvulsants for epilepsy or seizures, Parkinson's disease, diabetes mellitus
11. Any acute or chronic form of infection including Human immunodeficiency virus (HIV) infection or Lues of any stage (according to medical history or clinical signs and symptoms)
12. Known hypersensitivity to Rhodiola rosea extract
13. Gastrointestinal disorders with uncertain absorption of orally administered drugs (e.g. partial or total gastrectomy, enterectomy, inflammatory bowel disease, celiac disease, symptomatic lactose intolerance, other disorders associated with chronic diarrhoea)
14. Pregnancy, lactation
15. Women capable of childbearing if not using adequate contraception (intra-uterine devices, injectable contraception, oral contraceptives plus one other contraceptive measure)
16.Score of 14 or higher on Beck Depression Inventory II (BDI II)

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Universitätsklinikum Schleswig-Holstein

Sponsor information


Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Sponsor details

Willmar Schwabe Str. 4

Sponsor type




Funder type


Funder name

Dr Willmar Schwabe GmbH & Co. KG (Germany)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

26/05/2017: Plain English summary added.